SAN DIEGO, CA--(Marketwired - Mar 12, 2014) - Aegis Therapeutics LLC's Intravail® technology has been successfully formulated with phenylephrine in compressed tablets, dramatically improving oral ...

SAN DIEGO, Feb. 20, 2019 /PRNewswire/ -- Neurelis, Inc. announced today that its Intravail® licensing partner, ARS Pharmaceuticals, Inc., received Fast Track designation from the FDA for ARS-1, its ...

SAN DIEGO, CA--(Sep 24, 2012) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,268,791 providing fast acting formulations for triptans, a class of drugs that are ...

On July 19, 2017, Opiant Pharmaceuticals Inc. (OPNT) announced results from a Phase 1 study of OPNT002, an intranasally (IN) administered formulation of the opioid antagonist naltrexone hydrochloride.

SAN DIEGO, Calif.--(BUSINESS WIRE)--ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic ...

Company is targeting medications that together made over $1 billion in sales annually. Dr. Reddy’s Laboratories negotiated access to Aegis Therapeutics’ Intravail® drug-delivery technology for use ...

Dauntless Pharmaceuticals, Inc. (Dauntless), a biopharmaceutical company focused on the development of specialty drugs and Aegis Therapeutics, LLC (Aegis) today announced a licensing agreement ...

SAN DIEGO, Dec. 8, 2022 /PRNewswire/ -- ARS Pharmaceuticals, Inc., announced that the U.S. Food & Drug Administration (FDA) has accepted its New Drug Application (NDA) for neffy (previously referred ...

Pharmaceutical Technology is pleased to recognize the winners of its Innovations in Pharma Science Awards. Pharmaceutical Technology is pleased to recognize the winners of its Innovations in Pharma ...

SAN DIEGO, CA--(Marketwire - Sep 24, 2012) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,268,791 providing fast acting formulations for triptans, a class of drugs ...